Key Takeaways
- New Zealand's business confidence surged to an 11-year high of 67.1 in November, with the activity outlook also significantly improving to 53.1, signaling an economic recovery.
- The U.S. labor market deteriorated in November, as reported by the Federal Reserve's Beige Book, with employment declining slightly and overall consumer spending falling further.
- Novo Nordisk (NVO) shares advanced following the U.S. Medicare announcement of expected-level price reductions for 15 drugs, including Ozempic and Wegovy, effective 2027, with Ozempic seeing a negotiated price of $274 per month.
- Former President Donald Trump asserted that South Africa will be denied an invitation to the 2026 G20 summit in Miami, an action South Africa has denounced as punitive.
- Mexico's automotive industry is on high alert due to proposed steep tariff hikes and existing U.S. tariffs, which are already redirecting automotive investment away from the country.
U.S. Economic Activity Shows Signs of Weakness
The Federal Reserve's latest Beige Book, released on Wednesday, November 26, 2025, indicated a softening in the U.S. labor market during November. Employment declined slightly, and approximately half of the Federal Reserve Districts reported weaker labor demand. This comes as overall consumer spending continued to decline, though high-end retail spending remained resilient.
The report noted that some retailers experienced a negative impact on consumer purchases due to the recent government shutdown, and auto dealers saw a drop in EV sales following the expiration of a federal tax credit. Manufacturing activity increased somewhat, but tariffs and tariff uncertainty continued to act as a headwind.
New Zealand Business Confidence Soars to 11-Year High
New Zealand's business sentiment experienced a significant uplift in November 2025, with the ANZ Business Confidence Index surging to 67.1, up from 58.1 in October. This marks the highest level of confidence recorded in 11 years.
Accompanying this positive shift, the ANZ Activity Outlook also improved notably, rising to 53.1 from 44.6. This improvement in sentiment is reportedly rooted in an actual improvement in experienced activity, rather than just hopeful expectations, suggesting a sustained economic recovery is underway.
Novo Nordisk Shares Advance on Medicare Price Reductions
Shares of Novo Nordisk (NVO) advanced after the U.S. Medicare program announced negotiated price reductions for 15 high-cost prescription drugs. The price cuts, which are set to take effect in 2027, were largely in line with market expectations.
Among the drugs affected are Novo Nordisk's (NVO) popular semaglutide products, Ozempic and Wegovy. The negotiated monthly price for Ozempic will be $274, a significant reduction from its current list price of $959. Wegovy will see its higher doses priced at $385 per month. Earlier this month, Novo Nordisk (NVO) had reached an agreement with the Trump administration to lower drug prices starting in 2026, anticipating a low single-digit negative impact on its global sales growth for that year.
Trump Bars South Africa from 2026 G20 Summit
Former President Donald Trump announced on Wednesday, November 26, 2025, that South Africa would not receive an invitation to the 2026 G20 summit, which is scheduled to be hosted in Miami, Florida. This decision follows the U.S. boycott of the 2025 G20 summit held in Johannesburg.
Trump cited South Africa's refusal to hand over the G20 Presidency to a U.S. representative at the conclusion of the recent summit as a primary reason. He also reiterated claims of persecution of white Afrikaners in South Africa, which the South African government has consistently rejected as baseless. South Africa's presidency labeled Trump's action as "punitive" and based on "misinformation and distortions." Trump further stated his intention to stop all payments and subsidies to South Africa immediately.
Mexico's Auto Industry Alarmed by Tariff Hikes
Mexico's automotive sector is facing significant concerns over proposed steep tariff hikes and existing trade policies. The country's Ministry of Economy is reportedly considering tariffs of up to 50% on vehicles imported from nations without free trade agreements, including China.
This comes amidst ongoing challenges from new U.S. tariffs on raw materials and auto parts, which have already begun to redirect automotive investment away from Mexico. Companies like Ford (F) and General Motors (GM) anticipate impacts of $5 billion and $3 billion, respectively, from these tariffs. The upcoming review of the U.S.-Mexico-Canada Agreement (USMCA) in 2026 is also expected to potentially extend into 2027 and introduce stricter rules of origin for the automotive sector, further raising costs and uncertainty.
Intel Disputes TSMC's Trade Secret Allegations
Taiwan Semiconductor Manufacturing Co. (TSM) has filed a lawsuit against its former senior executive, Lo Wei-jen, accusing him of sharing sensitive trade secrets with U.S. chipmaker Intel (INTC). Lo, who retired from TSMC (TSM) in July 2025 and subsequently joined Intel (INTC) as an executive vice president, is suspected of taking confidential documents related to TSMC's (TSM) advanced 2-nanometer, A16, and A14 chip processes.
These technologies are considered critical for future chipmaking and represent the pinnacle of semiconductor manufacturing. Intel (INTC) has denied the allegations, with its CEO stating the company has strict internal controls and respects intellectual property. Taiwan prosecutors have launched an investigation into the alleged intellectual property theft.
Ed Liston is a senior contributing editor at TheStockMarketWatch.com. An active market watcher and investor, Ed guides an independent team of experienced analysts and writes for multiple stock trader publications.